Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 102
Filter
1.
Lymphat Res Biol ; 22(2): 163-187, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38630991
3.
Lymphat Res Biol ; 22(1): 66-88, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38394089
4.
Ann Otol Rhinol Laryngol ; 133(2): 145-151, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37551026

ABSTRACT

OBJECTIVE: To report our institutional experience in diagnosing and surveilling patients with infantile subglottic hemangioma (SGH) using in-office flexible fiberoptic laryngoscopy (FFL) with video technology, without requiring operative endoscopy in the era of propranolol use. METHODS: A retrospective case series was conducted on 4 children diagnosed with SGH between 2016 and 2022 at our institution. RESULTS: Awake FFL with video technology provided adequate visualization of SGH lesions for diagnosis, without any complications. Serial examinations of the airway were performed in the outpatient setting and each SGH gradually regressed, with marked improvement in respiratory symptoms within 48 hours of oral propranolol initiation. CONCLUSION: Our findings showed that in select patients, FFL with video technology can successfully identify SGH lesions without general anesthesia exposure. FFL may be used as a low-risk screening tool for propranolol therapy initiation in some patients, but operative endoscopy should remain the gold standard procedure for others. By utilizing FFL in this manner, it is possible to diagnose SGH lesions and start propranolol therapy without exposing all patients to the risks of operative endoscopy.


Subject(s)
Hemangioma , Laryngeal Neoplasms , Child , Humans , Infant , Propranolol/therapeutic use , Retrospective Studies , Laryngeal Neoplasms/diagnosis , Laryngeal Neoplasms/drug therapy , Laryngeal Neoplasms/pathology , Treatment Outcome , Hemangioma/diagnosis , Hemangioma/drug therapy , Hemangioma/pathology
5.
Lymphat Res Biol ; 21(6): 614-640, 2023 Dec.
Article in English | MEDLINE | ID: mdl-38149917
6.
Lymphat Res Biol ; 21(5): 504-533, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37870780
7.
Pediatr Dermatol ; 40(6): 996-1002, 2023.
Article in English | MEDLINE | ID: mdl-37845188

ABSTRACT

BACKGROUND/OBJECTIVES: Ulceration is a common complication of infantile hemangioma (IH). Severe, persistent ulceration occurs in a minority of patients. This study aims to characterize the clinical features of IH with aggressive ulceration (AU). METHODS: Multicenter retrospective study of clinical features of IH with AU. RESULTS: Thirty-five patients with AU were identified and included in the study. The majority of AU occurred in segmental IH (23/35, 65%). Segmental IH with AU were large (≥10 cm2 ; 16/23, 69%, p < .001) with a thin (<3 mm) superficial component (16/23, 69%, p < .001). Localized IH with AU had a thick (>3 mm) superficial component (11/12, 92%, p < .001). All diaper area IH with AU (9/35) were segmental with thin superficial component (100%, p = .02). IH with AU in the head/neck (10/35) were more commonly localized (67%) and mixed (62.5%), while segmental, thick superficial morphology was more common on trunk (9/35) and upper extremities (7/35). CONCLUSIONS: IH resulting in AU differ in clinical features by anatomic site. Those in the diaper area are nearly always segmental with thin superficial component, whereas other sites tend to be localized, mixed, with thick superficial component. These distinct phenotypes may prove useful in the clinical setting for physicians to identify patterns of IH ulceration with increased risk of aggressive, persistent ulceration.


Subject(s)
Hemangioma, Capillary , Hemangioma , Skin Neoplasms , Humans , Infant , Retrospective Studies , Hemangioma, Capillary/complications , Hemangioma/complications , Hemangioma/diagnosis , Upper Extremity , Skin , Skin Neoplasms/complications , Skin Neoplasms/diagnosis
8.
Lymphat Res Biol ; 21(4): 410-429, 2023 Aug.
Article in English | MEDLINE | ID: mdl-37616587
9.
Lymphat Res Biol ; 21(3): 314-335, 2023 Jun.
Article in English | MEDLINE | ID: mdl-37358829
10.
Lymphat Res Biol ; 21(2): 194-226, 2023 Apr.
Article in English | MEDLINE | ID: mdl-37093172
11.
Lymphat Res Biol ; 21(1): 78-96, 2023 Feb.
Article in English | MEDLINE | ID: mdl-36809167
13.
J Neurointerv Surg ; 15(3): 272-275, 2023 Mar.
Article in English | MEDLINE | ID: mdl-35347057

ABSTRACT

BACKGROUND: In the last few decades there has been development of innovative therapies for the treatment of craniofacial lymphatic malformations. Percutaneous sclerotherapy has demonstrated efficacy in the management of macrocystic lymphatic lesions, but it is less suitable for microcystic lesions given their size. The gravity-dependent technique is a novel augmentation of standard percutaneous sclerotherapy: the technique enables a sclerosing agent to permeate the small microchannels seen in microcystic lesions that would otherwise be difficult to treat. METHODS: Between 2005 and 2021, 124 patients with microcystic or mixed lymphatic malformations were treated using a novel gravity-dependent sclerotherapy technique. Bleomycin at a maximum dose of 15 IU per session was used as the main sclerosing agent. Fluoroscopy and ultrasound were used to ensure proper positioning of the catheter prior to injecting the sclerosing agent. The response to treatment was assessed clinically and with cross-sectional imaging. RESULTS: Nearly all cases showed significant improvement after the gravity-dependent technique. There have been no permanent complications from sclerotherapy treatment. There was a mild transient adverse effect from bleomycin in one case of erythema and tenderness that lasted several weeks then ameliorated. CONCLUSIONS: The gravity-dependent sclerotherapy technique is a suitable treatment option for microcystic lymphatic malformations.


Subject(s)
Lymphatic Abnormalities , Sclerotherapy , Humans , Bleomycin/therapeutic use , Lymphatic Abnormalities/diagnostic imaging , Lymphatic Abnormalities/therapy , Retrospective Studies , Sclerosing Solutions/therapeutic use , Sclerotherapy/methods , Treatment Outcome
14.
Pediatr Res ; 93(6): 1470-1479, 2023 05.
Article in English | MEDLINE | ID: mdl-36180586

ABSTRACT

BACKGROUND: We report a 3-month-old female with cardiovascular anomalies and diffuse intestinal infantile hemangioma (IIH) of the small bowel suggesting possible diagnosis of PHACE syndrome (posterior fossa anomalies, hemangioma, arterial lesions, cardiac abnormalities/coarctation of the aorta, eye anomalies). The GI symptoms persisted under treatment with propranolol, whereas the addition of sirolimus led to regression of the IIH. METHODS: A systematic review was conducted using PubMed, EMBASE, and Ovid MEDLINE databases between 1982 and 2021. RESULTS: A total of 4933 articles were identified; 24 articles met inclusion criteria with 46 IIH cases. The most common GI presentations were unspecified GI bleed (40%) and anemia (38%). The most common treatments were corticosteroids (63%), surgical resection (32.6%), and propranolol (28%). Available outcomes were primarily bleeding arrest (84%). Nine cases (19.5%) were diagnosed with definite PHACE, 5 (11%) with possible PHACE, and 32 (69.5%) no PHACE. Our case presented with symptoms most consistent with those of possible PHACE and definite PHACE. No cases in this review underwent treatment with sirolimus. CONCLUSIONS: This is the first reported case of successful treatment of IIH with sirolimus. Our case, along with other patients who present with IIH and PHACE features, suggests consideration of IIH as a diagnostic criterion for PHACE syndrome. IMPACT: This is the first reported case in which sirolimus showed regression of an intestinal infantile hemangioma. This study serves to demonstrate the presentation, treatment, outcomes of intestinal infantile hemangioma, and correlation with PHACE. The potential correlation between intestinal infantile hemangioma and PHACE deserves more study in consideration of intestinal infantile hemangioma as a diagnostic criterion of PHACE.


Subject(s)
Aortic Coarctation , Eye Abnormalities , Hemangioma, Capillary , Hemangioma , Humans , Female , Infant , Propranolol/therapeutic use , Aortic Coarctation/diagnosis , Eye Abnormalities/diagnosis , Hemangioma/diagnosis , Hemangioma/drug therapy , Hemangioma/pathology , Syndrome
15.
Lymphat Res Biol ; 20(6): 671-694, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36537708
16.
Lymphat Res Biol ; 20(5): 548-576, 2022 10.
Article in English | MEDLINE | ID: mdl-36302176
17.
Lymphat Res Biol ; 20(4): 443-464, 2022 08.
Article in English | MEDLINE | ID: mdl-35993922
19.
Lymphat Res Biol ; 20(3): 342-351, 2022 06.
Article in English | MEDLINE | ID: mdl-35687831
20.
Pediatr Dermatol ; 39(5): 718-726, 2022 Sep.
Article in English | MEDLINE | ID: mdl-35734850

ABSTRACT

BACKGROUND/OBJECTIVES: The COVID-19 pandemic prompted a rapid expansion in the use of telemedicine. This study aimed to assess the experiences of hemangioma specialists utilizing telemedicine during the COVID-19 pandemic to evaluate and manage infantile hemangiomas (IH), including perceived effectiveness of different modalities and barriers to care delivery. METHODS: Multicenter cross-sectional study asking providers to describe their experiences using telemedicine for initial evaluation of IH from March to September 2020. RESULTS: The study included 281 patients from 15 medical centers internationally. Median time from referral to evaluation was 17 days. Median physician confidence in performing evaluations via telemedicine was 95.0 (IQR 90.0-100.0). Most evaluations were performed via video communication with photographs or audio communication with photographs; when not initially available, photographs were requested in 51.4%. Providers preferred follow-up modalities that included photographs. CONCLUSIONS: Physicians with extensive expertise in managing IH are confident in their abilities to assess and manage IH via telemedicine including initiating treatment in patients without risk factors for beta-blocker therapy. There was a preference for hybrid modalities that included photographs. The data suggest that telemedicine can be effective for managing IH and may decrease wait times and improve specialist reach to underserved areas.


Subject(s)
COVID-19 , Hemangioma, Capillary , Hemangioma , Telemedicine , COVID-19/epidemiology , Cross-Sectional Studies , Hemangioma/diagnosis , Hemangioma/therapy , Humans , Pandemics
SELECTION OF CITATIONS
SEARCH DETAIL
...